BT3 Stock Chart & Stats
€1.35
€0.05(8.65%)
At close: 4:00 PM EST
€1.35
€0.05(8.65%)
Day’s Range― - ―
52-Week Range€0.79 - €1.68
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€240.51M
Enterprise Value€360.49
Total Cash (Recent Filing)€53.38M
Total Debt (Recent Filing)€2.39M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 06, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding249,298,300
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)8.63
Price to Sales (P/S)26.40
P/FCF Ratio-19.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.12Price Target Upside353.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.06
Revenue Forecast (FY)€13.44M
Bulls Say, Bears Say
Bulls Say
Scalable AlloSCOPE ManufacturingA reproducible, tiered banking approach and FDA-cleared final product create a durable manufacturing advantage for allogeneic, off‑the‑shelf therapies. Scale potential and lower per‑dose cost support commercial economics, supply consistency and competitive differentiation over multiple years.
Partner Validation And Clinic Expansion (OpRegen)Sustained single‑dose durability reported by a major partner and active site expansion materially de‑risks clinical validation and supports future commercialization pathways. Long‑term partner engagement provides development resources, regulatory credibility and access to broader clinical infrastructure.
Balance Sheet Flexibility And RunwayLow leverage and a multi‑year cash runway reduce immediate funding pressure, allowing focused R&D execution. Contingent warrants and sizable partner milestones provide optionality to finance scale‑up or de‑risk development without immediate dilutive financings.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow means the business depends on external financing or partner payments to sustain R&D and operations. This structural cash burn elevates funding risk and can constrain strategic optionality over the medium term if milestones or financings are delayed.
Deeply Negative ProfitabilityHigh gross margins reflect valuable product economics, but extreme negative net margins and widening losses show operating cost structure outpaces revenue. Until R&D and G&A scale with sustainable revenue, profitability remains an enduring constraint on capital efficiency and investor risk profiles.
Islet Program Scale And Technical RiskRequired per‑patient cell mass and uncertain bioreactor limits create a durable technical and cost‑of‑goods hurdle. Achieving consistent differentiation at multi‑liter scale and overcoming heterogeneity are structural risks that could delay commercialization or raise manufacturing costs materially.
Lineage Therap News
BT3 FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was €0.79 and its highest was €1.68 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is €240.51M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 14 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -€0.026 earnings per share for the quarter, missing the consensus estimate of -€0.018 by -€0.009.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.02.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 249,298,300 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -€0.026 in its last earnings report, missing expectations of -€0.018. Following the earnings report the stock price went up 3.704%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DE:BT3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lineage Therap Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.12 (353.24% Upside)
€6.12 (353.24% Upside)
Blogger Sentiment
Bullish
DE:BT3 Sentiment 70%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.99%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
BT3 Stock 12 Month Forecast
Average Price Target
€6.12
▲(353.24% Upside)
Technical Analysis
Amarin
―
Tvardi Therapeutics
―
DBV Technologies SA - American
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―